Kanako Akamatsu

Acquisition of resistance to wild-type spike-immune sera by emerging SARS-CoV-2 variants

J. Takagi, D. Standley, M. Okada, 2021 .

The SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccines

D. Standley, A. Nakagawa, M. Okada, 2021, bioRxiv.

An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies

D. Standley, Masahiro Yamamoto, K. Ohmura, 2021, Cell.

SRC kinase activator CDCP1 promotes hepatocyte growth factor–induced cell migration/invasion of a subset of breast cancer cells

M. Ueda, S. Nada, M. Okada, 2022, The Journal of biological chemistry.

An engineered ACE2 decoy broadly neutralizes Omicron subvariants and shows therapeutic effect in SARS-CoV-2-infected cynomolgus macaques

Takanori Sasaki, M. Okada, Y. Matsuura, 2023, bioRxiv.

An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models

Takanori Sasaki, M. Okada, Y. Matsuura, 2023, Science Translational Medicine.